Yester Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 05-12-2024
- Paid Up Capital ₹ 5.00 M
as on 05-12-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.85 Cr
as on 05-12-2024
About Yester Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.85 Cr.
Shashi Garg, Atul Garg, and Ram Garg serve as directors at the Company.
- CIN/LLPIN
U24304HP2020PTC007903
- Company No.
007903
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Yester Pharma Private Limited offer?
Yester Pharma Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Digestive System Drugs & Medicines, Antacid Drugs, Common Disease Medicines, Antihistamines, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Yester Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Garg  | Director | 08-Jun-2020 | Current |
| Shashi Garg | Director | 08-Jun-2020 | Current |
| Ram Garg | Director | 08-Jun-2020 | Current |
Financial Performance of Yester Pharma.
Yester Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Yester Pharma?
In 2021, Yester Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Soft Touch Pharmaceutical India LimitedActive 21 years 4 monthsShashi Garg, Atul Garg and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Dec 2022 | ₹3.50 M | Open |
Others Creation Date: 03 Dec 2020 | ₹1.50 Cr | Open |
How Many Employees Work at Yester Pharma?
Yester Pharma has a workforce of 20 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Yester Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Yester Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
